Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX

NCT01834235 is registered in ClinicalTrials.gov with Precision Biologics, Inc as lead sponsor.

NCT NCT01834235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01834235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
Lead sponsor
Precision Biologics, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2013
Completion date
December 31, 2019
Enrollment
81 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, adult